卵巢功能抑制对35岁以下中国乳腺癌患者心理状态的影响
该横断面研究纳入91例35岁及以下中国乳腺癌术后患者,采用PHQ-9和GAD-7评估心理状态。结果显示,接受卵巢功能抑制(OFS)者抑郁发生率显著高于未接受者(31.1% vs 6.7%,P=0.018),焦虑发生率无显著差异(13.1% vs 3.3%,P=0.174);多因素分析中OFS仍与抑郁发生显著相关(OR=9.14,95%CI=1.52~55.16,P=0.016)。
要点
- ≤35岁乳腺癌患者中,OFS组抑郁发生率为31.1%,未OFS组为6.7%(P=0.018)。
- 多因素分析显示OFS与抑郁发生独立相关(OR=9.14,95%CI=1.52~55.16,P=0.016)。
- 两组焦虑发生率差异无统计学意义(13.1% vs 3.3%,P=0.174)。
核心结论
- 在≤35岁中国乳腺癌患者辅助内分泌治疗中,应用OFS可能显著增加抑郁发生率。
研究设计与样本
- 横断面研究,纳入91例35岁及以下中国乳腺癌术后患者,61例接受含OFS的内分泌治疗,30例未接受OFS。
主要发现
- OFS组与非OFS组抑郁发生率分别为31.1%和6.7%,差异有统计学意义(P=0.018)。
- OFS组与非OFS组焦虑发生率分别为13.1%和3.3%,差异无统计学意义(P=0.174)。
- 多因素分析显示OFS与抑郁发生仍显著相关(OR=9.14,95%CI=1.52~55.16,P=0.016)。
关键数值与推荐
- 抑郁评估采用PHQ-9,得分≥8分定义为抑郁;焦虑评估采用GAD-7,得分≥10分定义为焦虑。
- 非OFS组30例中PHQ-9≥8分2例、GAD-7≥10分1例;OFS组61例中PHQ-9≥8分19例、GAD-7≥10分8例。
临床怎么用
- 对≤35岁接受OFS的乳腺癌患者,应重视抑郁状态的评估与监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore whether the addition of ovarian function suppression in endocrine therapy of Chinese breast cancer patients under 35 years old will affect the psychological state. Methods: This cross-sectional study enrolled 91 Chinese postoperative breast cancer patients aged 35 years or younger. The depression and anxiety state of patients were assessed by Patient Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7), and their sociodemographic characteristics were collected. Results: Among the 91 patients, 61 were receiving ovarian function suppression (OFS) treatment, 30 were not. Among the 30 patients with out OFS treatment, 2 had PHQ-9 score ≥8, 28 had PHQ-9 score < 8, 1 had GAD-7 score ≥10, and 29 had GAD-7 score < 10. Among the 61 patients with OFS, 19 had PHQ-9 score ≥8, 42 had PHQ-9 score < 8, 8 had GAD-7 score ≥10, and 53 had GAD-7 score <10. The incidence of depression was 6.7% and 31.1% in the non-OFS group and OFS group, respectively (P=0.018). The incidence of anxiety in the two groups was 3.3% and 13.1%, respectively (P=0.174). Univariate analysis showed that the incidence of depression was significantly higher in patients with OFS (P=0.018). After taking into account the sociodemographic factors, pathological stage and treatment of the patients, multivariate analysis showed that the administration of OFS was still significantly related to the incidence of depression (OR=9.14, 95% CI=1.52~55.16, P=0.016). There was no significant difference in the incidence of anxiety (P=0.174). Conclusions: For Chinese young breast cancer patients under 35 years old, the use of OFS in the adjuvant endocrine therapy may lead to a significant increase in the incidence of depression. We should pay attention to the evaluation and monitoring of the psychological state of this population. 目的: 分析≤35岁中国乳腺癌患者内分泌治疗中卵巢功能抑制对患者抑郁、焦虑等心理状态的影响。 方法: 收集2018—2019年就诊于中国医学科学院肿瘤医院乳腺内科门诊且正在接受辅助内分泌治疗的91例乳腺癌术后患者的人口社会学特征、临床病理资料和治疗方案。 采用患者健康问卷抑郁量表(PHQ-9)和广泛性焦虑量表(GAD-7)评估患者的抑郁和焦虑状态。 结果: 91例患者中,61例正在行含有卵巢功能抑制的内分泌治疗,30例未行卵巢功能抑制治疗。未行卵巢功能抑制的30例患者中,PHQ-9得分≥8分2例,PHQ-9得分<8分28例;GAD-7得分≥10分1例,GAD-7得分<10分29例。行卵巢功能抑制的61例患者中,PHQ-9得分≥8分19例,PHQ-9得分<8分42例;GAD-7得分≥10分8例,GAD-7得分<10分53例。未行卵巢功能抑制组和行卵巢功能抑制组患者的抑郁发生率分别为6.7%和31.1%,差异有统计学意义(P=0.018);焦虑发生率分别为3.3%和13.1%,差异无统计学意义(P=0.174)。多因素分析显示,内分泌治疗和居住状态与患者发生抑郁均有关(均P<0.05)。 结论: 在≤35岁中国年轻乳腺癌患者的内分泌治疗中,应用卵巢功能抑制药物可能会造成抑郁症状发生率较高,应重视对这一人群心理状态的评估监测。.
引用
- Lan B, Jiang SY, Li T, et al. [The effect of ovarian function suppression on the psychological status of breast cancer patients under 35 years old in China]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32842448. doi:10.3760/cma.j.cn112152-20191101-00708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。